Overall, we have, for the first time, successfully provided evidence that THOP1 could be a therapeutic target for controlling obesity and associated diseases, such as insulin resistance and NAFLS. This evidence concerns the gene THOP1 and obesity due to melanocortin 4 receptor deficiency.